Product Description
mRNA‑6231 is a lipid nanoparticle (LNP)‑encapsulated mRNA-based therapeutic that encodes for mutein human interleukin 2, fused to human serum albumin (HSA‑IL2m), with the goal of achieving enhanced selectivity toward T regulatory cells. IL-2 through preferential expansion of Tregs is hypothesized to play a central role in restoring immune homeostasis. (Sourced from: https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-1-Study-of-Its-IL-2-mRNA-Therapeutic/default.aspx)
Mechanisms of Action: IL2 Agonist
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Moderna
Company Location: Eastern America
Company Founding Year: 2010
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04916431 |
mRNA-6231-P101 | P1 |
Completed |
Healthy Volunteers |
2022-08-02 |
88% |
2022-08-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/04/2021 |
News Article |
Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates |
|
08/05/2021 |
News Article |
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates |
|
08/02/2021 |
News Article |
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic |
|
05/06/2021 |
News Article |
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates |